RT Journal Article
T1 Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy.
A1 Bieback, Karen
A1 Fernandez-Muñoz, Beatriz
A1 Pati, Shibani
A1 Schäfer, Richard
K1 cell culture supplement
K1 cell therapy
K1 fetal bovine serum
K1 human platelet lysate
K1 pathogen reduction treatment
K1 Unidad de Producción y Reprogramación Celular (UPRC)
K1 Laboratorio Andaluz de Reprogramación Celular (LARCEL)
K1 Iniciativa Andaluza de Terapias Avanzadas, Sevilla
AB Fetal bovine serum (FBS) is used as a growth supplement in a wide range of cell culture applications for cell-based research and therapy. However, as a xenogenic product, FBS can potentially transmit prions and adventitious viruses as well as induce undesirable immunologic reactions. In addition, the use of bovine fetuses for FBS production raises concerns as society looks for ways to replace animal testing and reduce the use of animal products for scientific purposes, in particular for the manufacture of clinical products intended for human use. Until chemically defined media are available for these purposes, human platelet lysate (hPL) has been introduced as an attractive alternative for replacing FBS as a cell culture supplement. hPL is a human product that can be produced from outdated platelets avoiding ethical, medical and animal welfare concerns. An increasing number of studies demonstrate that hPL can promote cell growth similarly or even better than FBS in specific cell types. Due to increasing interest in hPL, the AABB and the International Society of Cell Therapy (ISCT) established a joint working group to address its potential. With this article, we aim to present an overview of hPL, identifying the gaps in information on how hPL is produced and tested and the barriers to its translational use in the production of clinical-grade cell therapy products.
PB Cytotherapy
YR 2019
FD 2019-07-12
LK https://hdl.handle.net/10668/27909
UL https://hdl.handle.net/10668/27909
LA en
NO Bieback K, Fernandez-Muñoz B, Pati S, Schäfer R. Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy. Cytotherapy. 2019 Sep;21(9):911-924.
DS RISalud
RD Apr 8, 2025